Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL769464

CSC.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
TSHR P16473 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.36
THRB P10828 1/20 0.35
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
TP53 P04637 1/20 0.33
CA2 P00918 1/20 0.33
CES1 P23141 2/20 0.32
FFAR3 O14843 1/20 0.31
LCK P06239 1/20 0.31
FYN P06241 1/20 0.31
ACLY P53396 2/20 0.31
F2 P00734 1/20 0.31
F11 P03951 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
FAAH O00519 1/20 0.31
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6117652 0.97 ALDH1A1 (0.37) ALDH1A1TSHRL3MBTL1THRBNOS1
Trifluoroacetic Acid SCHEMBL1262416 0.85
Trifluoroacetic Acid SCHEMBL72727 0.85
Trifluoroacetic Acid SCHEMBL3499424 0.85
Trifluoroacetic Acid SCHEMBL2484766 0.84 ALDH1A1 (0.44) ALDH1A1TSHRL3MBTL1THRBTP53
Trifluoroacetic Acid SCHEMBL4598430 0.84
Trifluoroacetic Acid SCHEMBL30657022 0.84
Trifluoroacetic Acid SCHEMBL474 0.84
Trifluoroacetic Acid SCHEMBL7814389 0.84 ALDH1A1 (0.44) ALDH1A1TSHRL3MBTL1THRBTP53
Trifluoroacetic Acid SCHEMBL1731636 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3738591-A2 NOVEL ANTIBACTERIAL AGENTS MERCK SHARP & DOHME CORP. (US) 2020-11-18 EP disclosed
CN-107405319-A Antifibrinolysis compound 希罗姆波尔蒂克斯有限责任公司 2017-11-28 CN disclosed
US-20160280718-A1 NOVEL ANTIBACTERIAL AGENTS MERCK SHARP & DOHME (US) 2016-09-29 US disclosed
US-9200026-B2 Antibacterial agents MERCK SHARP & DOHME CORP. (US) 2015-12-01 US disclosed
EP-2664331-B1 Novel Antibacterial Agents MERCK SHARP & DOHME (US) 2015-09-16 EP disclosed
EP-2772254-A2 Novel Antibacterial Agents Optimer Pharmaceuticals, Inc. (US) 2014-09-03 EP disclosed
US-20130345410-A1 NOVEL ANTIBACTERIAL AGENTS OPTIMER PHARMACEUTICALS, INC. (US) 2013-12-26 US disclosed
EP-2664331-A1 Novel Antibacterial Agents Optimer Pharmaceuticals, Inc. (US) 2013-11-20 EP disclosed
US-8343936-B2 Antibacterial agents OPTIMER PHARMACEUTICALS, INC. (US) 2013-01-01 US disclosed
US-20120071429-A1 Novel antibacterial agents TETARD, INC. 2012-03-22 US disclosed
WO-1997007131-A1 ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES NOVARTIS AG (CH) 1997-02-27 WO disclosed
US-5459063-A Antimalarial agents THE UNIVERSITY OF PENNSYLVANIA (US) 1995-10-17 US disclosed
US-5254682-A Treating hypertension, hyperaldosteronism, congestive heart failure; glaucoma MERCK & CO., INC. (US) 1993-10-19 US disclosed
EP-0518675-A2 Cyclic renin inhibitors MERCK & CO. INC. (US) 1992-12-16 EP disclosed
EP-0518672-A2 Cyclic renin inhibitors MERCK & CO. INC. (US) 1992-12-16 EP disclosed
EP-0435996-A4 MODIFIED TRANSFORMING GROWTH FACTOR -G(A) OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF 1992-07-29 EP disclosed
EP-0435996-A1 MODIFIED TRANSFORMING GROWTH FACTOR $g(a) OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE ROCKEFELLER UNIVERSITY (US) 1991-07-10 EP disclosed
EP-0432974-A1 Cyclic renin inhibitors MERCK & CO. INC. (US) 1991-06-19 EP disclosed
EP-0431972-A2 Macrocyclic lactones having renin inhibiting properties MERCK & CO. INC. (US) 1991-06-12 EP disclosed
WO-1991001141-A1 MODIFIED TRANSFORMING GROWTH FACTOR α OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE ROCKEFELLER UNIVERSITY (US) 1991-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345410-A1 NOVEL ANTIBACTERIAL AGENTS MRPL21, CTSA, MRPL12 ALDH1A1 4594/4885TSHR 3227/4885L3MBTL1 2037/4885
US-20160280718-A1 NOVEL ANTIBACTERIAL AGENTS MRPL21, MRPL12, CTSA ALDH1A1 4735/4885TSHR 3235/4885L3MBTL1 2103/4885
US-20120071429-A1 Novel antibacterial agents MRPL21, CTSA, MRPL12 ALDH1A1 4594/4885TSHR 3227/4885L3MBTL1 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.